Multiple Uses for Gamma Knife™ Drives Market Growth Through 2025

For over four decades, patients have benefited from treatment with Gamma Knife™ radiosurgery for a variety of medical conditions. Due to its widespread success in the treatment of several types of brain cancer, global market growth for Gamma Knife™ treatment involving the head—which dominates the market share at over 88.1%—is expected to exceed $364.8 million by 2025.(1) As more patients seek treatment at facilities which offer Gamma Knife™ radiosurgery, such as the San Diego Gamma Knife Center® (SDGKC), the market is forecast to grow at a compound annual growth rate (CAGR) of 9.2%.(1)

In terms of geographical location, North America has traditionally led market revenue share, accounting for over 29.2% of revenue in 2014.(1) By 2025, treatment of brain metastasis is expected to account for over $285.7 million in the United States market alone.(2) However, as more patients worldwide are treated using Gamma Knife™ for a variety of medical conditions (for example, brain metastases, benign brain tumors such as pituitary adenomas, meningiomas and acoustic neuromas. Both the European and Asia Pacific markets are expected to expand at CAGRs of 7.7% and 10.5%, respectively.(1)

A large part of this growth is the confirmation of the Gamma Knife™ an effective treatment option for a wide variety of medical conditions that benefit from a precision approach. Beyond its use as a successful therapy for metastatic brain tumors, the Gamma Knife™ has provided powerful results to patients suffering from trigeminal neuralgia, movement disorders, and arteriovenous malformations.(3)

Dr. Kenneth Ott, Neurosurgeon at SDGKC, said, “The need for the radiosurgical treatment of metastatic brain tumors is vast and growing. Radiosurgery will also play an important part in the emerging field of neuro-augmentation. Stereotactic…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *